KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents
Summary
This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.
Questions topics -
- Further Phase I data required for Roche’s capsid inhibitor RO7049389
- Replicor’s US trial plans and transition from IV to subcutaneous REP 2139
- Efficacy of Spring Bank’s inarigivir at 100mg in the Phase II ACHIEVE trial
- Expected role for inarigivir in HBV
- Efficacy of Arbut
Read More
- Table of Contents
- Executive Summary
- Background
- Research Panel Composition
- Results & Implications
- Appendix
Read More